Terms: = Liver cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
12 results:
1. Case Report: Complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor.
Wang Q; Mu Y; Ji S; Liu Y; Lou Y; Wei S; Dong X; Zhang B
Front Immunol; 2023; 14():1173520. PubMed ID: 37841278
[TBL] [Abstract] [Full Text] [Related]
2. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.
Yang Z; Xie H; Wan J; Wang Y; Zhang L; Zhou K; Tang H; Zhao W; Wang H; Song P; Zheng S
EBioMedicine; 2023 Jun; 92():104594. PubMed ID: 37167784
[TBL] [Abstract] [Full Text] [Related]
3. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression.
Cheng CS; Tan HY; Wang N; Chen L; Meng Z; Chen Z; Feng Y
Clin Transl Med; 2021 Jun; 11(6):e467. PubMed ID: 34185423
[TBL] [Abstract] [Full Text] [Related]
4. Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report.
Zielli T; Gnetti L; Buti S
Tumori; 2020 Dec; 106(6):NP79-NP83. PubMed ID: 32458743
[TBL] [Abstract] [Full Text] [Related]
5. Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis.
Xia C; Zeng H; Zheng Y
Mol Med Rep; 2020 Mar; 21(3):989-998. PubMed ID: 32016465
[TBL] [Abstract] [Full Text] [Related]
6. Elevated TRIP13 drives the AKT/mtor pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract] [Full Text] [Related]
7. Role of SIRT-3, p-mtor and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.
De Matteis S; Scarpi E; Granato AM; Vespasiani-Gentilucci U; La Barba G; Foschi FG; Bandini E; Ghetti M; Marisi G; Cravero P; Gramantieri L; Cucchetti A; Ercolani G; Santini D; Frassineti GL; Faloppi L; Scartozzi M; Cascinu S; Casadei-Gardini A
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30917505
[TBL] [Abstract] [Full Text] [Related]
8. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract] [Full Text] [Related]
9. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells.
Liu X; Liao W; Yuan Q; Ou Y; Huang J
Oncotarget; 2015 Oct; 6(33):34309-20. PubMed ID: 26418879
[TBL] [Abstract] [Full Text] [Related]
10. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate cancer Pretreated With Docetaxel Chemotherapy: A Prostate cancer clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract] [Full Text] [Related]
11. mtor in viral hepatitis and hepatocellular carcinoma: function and treatment.
Wang Z; Jin W; Jin H; Wang X
Biomed Res Int; 2014; 2014():735672. PubMed ID: 24804240
[TBL] [Abstract] [Full Text] [Related]
12. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract] [Full Text] [Related]